Hemizygous Tg(KRT14-cre)1Amc/J (also known as K14-Cre) transgenic mice were developed in the laboratory of Dr. Andrew P. McMahon at Harvard University. The mouse strain harbors Cre recombinase under the control of human keratin-14 promoter, which enables conditional Cre recombinase expression in the ectoderm and its derivatives. Cre expression was detected in the oral ectoderm at 11.75 dpc, and in the skin and dental epithelium at 14.5 dpc (Development 2000). KRT14-Cre mice are viable, fertile, normal in size and do not display any gross abnormalities.
The mice can be used as a tool model to study gene function in ectoderm and its derivatives during development.
The detailed description of the mouse strain can be found here.
The mouse strain is available for licensing from Harvard University and will be provided by The Jackson Laboratory.